Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.50 -3.0%	$4.45	$1.72 ▼ $8.21	$614.37M	2.18	3.10 million shs	3.13 million shs
EOLS Evolus	$6.57 +1.1%	$5.06	$3.86 ▼ $10.62	$428.06M	1.28	1.02 million shs	985,706 shs
FBRX Forte Biosciences	$20.97 -9.3%	$27.35	$7.00 ▼ $35.80	$320.90M	3.01	215,233 shs	357,792 shs
MTEM Molecular Templates		$0.00	$0.00 ▼ $1.59	$1K	1.53	5.62 million shs	N/A
TXMD TherapeuticsMD	$2.02 +1.0%	$2.12	$0.98 ▼ $2.95	$23.15M	0.58	21,545 shs	12,029 shs

The 10 Best AI Stocks to Own in 2026

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-9.30%	-25.10%	-32.14%	+77.83%
EOLS Evolus	0.00%	+2.20%	+38.59%	+51.16%	-32.99%
FBRX Forte Biosciences	0.00%	-3.79%	-31.87%	-28.03%	+194.39%
MTEM Molecular Templates	0.00%	0.00%	0.00%	0.00%	0.00%
TXMD TherapeuticsMD	0.00%	+1.01%	-3.38%	-15.25%	+33.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.50 -3.0%	$4.45	$1.72 ▼ $8.21	$614.37M	2.18	3.10 million shs	3.13 million shs
EOLS Evolus	$6.57 +1.1%	$5.06	$3.86 ▼ $10.62	$428.06M	1.28	1.02 million shs	985,706 shs
FBRX Forte Biosciences	$20.97 -9.3%	$27.35	$7.00 ▼ $35.80	$320.90M	3.01	215,233 shs	357,792 shs
MTEM Molecular Templates		$0.00	$0.00 ▼ $1.59	$1K	1.53	5.62 million shs	N/A
TXMD TherapeuticsMD	$2.02 +1.0%	$2.12	$0.98 ▼ $2.95	$23.15M	0.58	21,545 shs	12,029 shs

The 10 Best AI Stocks to Own in 2026

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-9.30%	-25.10%	-32.14%	+77.83%
EOLS Evolus	0.00%	+2.20%	+38.59%	+51.16%	-32.99%
FBRX Forte Biosciences	0.00%	-3.79%	-31.87%	-28.03%	+194.39%
MTEM Molecular Templates	0.00%	0.00%	0.00%	0.00%	0.00%
TXMD TherapeuticsMD	0.00%	+1.01%	-3.38%	-15.25%	+33.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.80	Moderate Buy	$12.78	265.08% Upside
EOLS Evolus	2.50	Moderate Buy	$16.00	143.53% Upside
FBRX Forte Biosciences	2.50	Moderate Buy	$67.00	219.50% Upside
MTEM Molecular Templates	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/11/2026	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $11.00
4/24/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/6/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D-)
3/27/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
3/23/2026	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $12.00
3/19/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
3/19/2026	CTMX CytomX Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $16.00
3/18/2026	CTMX CytomX Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $16.00
3/18/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$10.00 ➝ $15.00
3/17/2026	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$6.00 ➝ $11.00

(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	7.82	N/A	N/A	$0.58 per share	6.03
EOLS Evolus	$297.18M	1.46	N/A	N/A	($0.36) per share	-18.25
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$4.71 per share	N/A
MTEM Molecular Templates	$23.48M	0.00	N/A	N/A	$0.78 per share	0.00
TXMD TherapeuticsMD	$3.02M	7.74	$0.05 per share	42.87	$2.32 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.41	N/A	N/A	N/A	-166.40%	-36.61%	-28.02%	8/6/2026 (Estimated)
EOLS Evolus	-$51.64M	-$0.67	N/A	328.50	N/A	-14.39%	N/A	-19.03%	8/4/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.64	N/A	N/A	N/A	N/A	-106.17%	-85.50%	5/21/2026 (Estimated)
MTEM Molecular Templates	-$8.12M	-$2.70	N/A	N/A	N/A	-61.35%	-260.50%	-46.90%	N/A
TXMD TherapeuticsMD	-$570K	-$0.01	N/A	N/A	N/A	5.34%	0.32%	0.23%	N/A

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2026	Q1 2026	FBRX Forte Biosciences	-$1.16	N/A	N/A	N/A	N/A	N/A
5/12/2026	Q1 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.72 million
5/11/2026	Q1 2026	FBRX Forte Biosciences	-$1.16	-$1.24	-$0.08	-$1.24	N/A	N/A
5/7/2026	Q1 2026	CTMX CytomX Therapeutics	-$0.14	-$0.10	+$0.04	-$0.10	$4.68 million	$10.26 million
5/4/2026	Q1 2026	EOLS Evolus	-$0.14	-$0.16	-$0.02	-$0.16	$72.52 million	$73.14 million
3/31/2026	Q4 2025	FBRX Forte Biosciences	-$1.42	-$1.45	-$0.03	-$1.45	N/A	N/A
3/30/2026	Q4 2025	TXMD TherapeuticsMD	-$6.1250	-$0.0530	+$6.0720	-$0.05	$19.77 million	$0.89 million
3/16/2026	Q4 2025	CTMX CytomX Therapeutics	-$0.08	-$0.22	-$0.14	-$0.22	$7.33 million	$0.66 million
3/3/2026	Q4 2025	EOLS Evolus	$0.09	$0.0020	-$0.0880	N/A	$89.58 million	$90.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	10.38	10.38
EOLS Evolus	N/A	2.04	1.68
FBRX Forte Biosciences	N/A	2.75	2.75
MTEM Molecular Templates	N/A	1.56	1.56
TXMD TherapeuticsMD	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EOLS Evolus	90.69%
FBRX Forte Biosciences	77.63%
MTEM Molecular Templates	95.47%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EOLS Evolus	5.00%
FBRX Forte Biosciences	4.40%
MTEM Molecular Templates	13.90%
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	170.19 million	158.96 million	Optionable
EOLS Evolus	170	65.86 million	62.56 million	Optionable
FBRX Forte Biosciences	5	13.89 million	13.28 million	Optionable
MTEM Molecular Templates	260	6.58 million	5.67 million	No Data
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

EOLS, CTMX, FBRX, MTEM, and TXMD Headlines

Recent News About These Companies

TherapeuticsMD (NASDAQ:TXMD) vs. Plus Therapeutics (NASDAQ:PSTV) Head to Head Review

May 14, 2026 | americanbankingnews.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, CTMX, FBRX, MTEM, and TXMD Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.50 -0.11 (-3.05%)

Closing price 04:00 PM Eastern

Extended Trading

$3.59 +0.09 (+2.57%)

As of 05:04 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Evolus NASDAQ:EOLS

$6.57 +0.07 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$6.57 0.00 (0.00%)

As of 07:41 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Forte Biosciences NASDAQ:FBRX

$20.97 -2.14 (-9.26%)

Closing price 04:00 PM Eastern

Extended Trading

$21.01 +0.04 (+0.19%)

As of 07:30 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

TherapeuticsMD NASDAQ:TXMD

$2.02 +0.02 (+1.00%)

As of 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EOLS, CTMX, FBRX, MTEM, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, CTMX, FBRX, MTEM, and TXMD Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Evolus NASDAQ:EOLS

Forte Biosciences NASDAQ:FBRX

Molecular Templates NASDAQ:MTEM

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EOLS, CTMX, FBRX, MTEM, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, CTMX, FBRX, MTEM, and TXMD Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Evolus NASDAQ:EOLS

Forte Biosciences NASDAQ:FBRX

Molecular Templates NASDAQ:MTEM

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools